World Allergy Organ J. 2020 Mar 7;13(2):100091. doi: 10.1016/j.waojou.2019.100091. eCollection 2020 Feb.
Precision allergy molecular diagnostic applications (PAMD@) is increasingly entering routine care. Currently, more than 130 allergenic molecules from more than 50 allergy sources are commercially available for specific immunoglobulin E (sIgE) testing. Since the last publication of this consensus document, a great deal of new information has become available regarding this topic, with over 100 publications in the last year alone. It thus seems quite reasonable to publish an update. It is imperative that clinicians and immunologists specifically trained in allergology keep abreast of the new and rapidly evolving evidence available for PAMD@. PAMD@ may initially appear complex to interpret; however, with increasing experience, the information gained provides relevant information for the allergist. This is especially true for food allergy, allergy, and for the selection of allergen immunotherapy. Nevertheless, all sIgE tests, including PAMD@, should be evaluated within the framework of a patient's clinical history, because allergen sensitization does not necessarily imply clinical relevant allergies.
精准过敏分子诊断应用（PAMD@）正越来越多地进入常规医疗。目前，有超过50种过敏源的130多种致敏分子可用于商业性特异性免疫球蛋白E（sIgE）检测。自本共识文件上次发布以来，关于该主题已有大量新信息，仅去年就有100多篇相关出版物。因此，发布更新版本似乎相当合理。接受过变态反应学专门培训的临床医生和免疫学家必须紧跟PAMD@方面新出现且迅速发展的证据。PAMD@最初可能看起来难以解读；然而，随着经验的增加，所获得的信息能为过敏症专科医生提供相关信息。这在食物过敏、过敏以及变应原免疫疗法的选择方面尤其如此。尽管如此，所有sIgE检测，包括PAMD@，都应在患者临床病史的框架内进行评估，因为变应原致敏不一定意味着存在临床相关的过敏。
